Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 7Thoracic 6Gastrointestinal 5Genitourinary 4Lymphoid 3Tumor-Agnostic 2Gynecologic 2Sarcoma 1Plasma cell 1Other solid neoplasm 1Head & Neck 1Endocrine 1Dermatologic 1Breast 1

Conditions

Mesothelioma, Malignant 1

Interventions

pembrolizumab 26Cisplatin 15Pemetrexed 14Paclitaxel 14Carboplatin 14Nivolumab 10Cyclophosphamide 10Docetaxel 8atezolizumab 7Injections 7Melphalan 6tislelizumab 5olaparib 5Gemcitabine 5Filgrastim 5durvalumab 4aldesleukin 4Leucovorin 4Irinotecan 4Granulocyte Colony-Stimulating Factor 4Etoposide 4Bevacizumab 4tocilizumab 3spartalizumab 3liposomal doxorubicin 3ixabepilone 3fludarabine 3epacadostat 3defactinib 3adavosertib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × antineoplaston A10 × Other solid neoplasm × Clear all
NCT00003508 2021-04-27

Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma

Burzynski Research Institute

Phase 2 Terminated
8 enrolled 5 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡